Can a simple test predict immunotherapy success in head and neck cancer?

NCT ID NCT05328024

Recruiting now Knowledge-focused Sponsor: Centre Paul Strauss Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is collecting blood and tumor samples from 60 people with recurrent or metastatic head and neck cancer who are receiving standard anti-PD1 immunotherapy. The goal is to find biological markers that can predict whether the immunotherapy will work. Researchers will analyze the samples to see if certain genetic signatures are linked to better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anti-PD1 immunotherapy
What this could lead to: If successful, this could help doctors predict which patients will benefit from anti-PD1 immunotherapy, leading to more personalized treatment.
What could go wrong: This is an observational study, not a treatment trial. It may not identify reliable biomarkers, and results may not change current practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER

Contacts and locations

Locations

Institut de cancérologie Strasbourg Europe
RECRUITING

Strasbourg, France, 67033, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.